Clinical Epigenetics · 2014 · 21 citations · 19 references
Life SciencesMolecular BiologyOncologyCytogeneticsEpigeneticsMolecular OncologyCancer EpigeneticsDna Methylation ProfilingEpigenetic Alterations In CancerEpigenetic Regulation In CancerMolecular CytogeneticsMultiple MyelomaAberrant Dna MethylationCpg Island Promoter MethylationPromoter Cpg IslandsPromoter HypermethylationPromoter MethylationPromoter Methylation AnalysisTumor Suppressor Gene HypermethylationTumor Suppressor Gene Methylation
BACKGROUND: Aberrant DNA methylation of promoter region CpG islands is an alternative mechanism that leads to genetic defects in the inactivation of tumor suppressor genes during myelomagenesis. The aim of this study was to examine the promoter methylation status of the phosphates and tensin homologue on chromosome 10 (PTEN) gene in a cohort of multiple myeloma patients. FINDINGS: The PTEN gene was hypermethylated in 7 out of 58 (12%) primary myeloma samples. The correlation between functional inactivation and PTEN mRNA levels was not statistically significant. The multiple myeloma subgroup with an aberrant PTEN status had a prevalence of the component IgG, Salmon Durie stage I, lower lactate dehydrogenase levels, intermediate-standard cytogenetic risk and longer overall survival with the respect to the unmethylated subgroup. CONCLUSIONS: This is the first report demonstrating the presence of PTEN promoter hypermethylation in multiple myeloma.
19
Jing Li, Clifford Yen, Danny Liaw et al. · Science · 1997 · 4.8K citations
Shaji Kumar, Joseph Mıkhael, Francis K. Buadi et al. · Mayo Clinic Proceedings · 2009 · 625 citations · Full text
Medicine, Hematology, Oncology +14